Fujitsu successfully verifies AI technology to improve efficiency in cancer genomic medicine

Fujitsu successfully verifies AI technology to improve efficiency in cancer genomic medicine

Publication date: Nov 07, 2019

As part of this joint research, Fujitsu Laboratories Ltd. has successfully developed and verified AI technology to improve the efficiency of treatment planning in cancer genomic medicine, demonstrating its effectiveness through verification experiments at the Institute of Medical Science at the University of Tokyo.

Verification trial experiments using this technology have allowed the Department of Hematology and Oncology at the Institute of Medical Science, the University of Tokyo to reduce the amount of work required to determine a treatment plan for acute myeloid leukemia by more than half, delivering improved efficiency.

To address these challenges, Fujitsu Laboratories and the Institute of Medical Science at the University of Tokyo’s launched a joint AI research project beginning in April 2018 to improve the efficiency and sophistication of the work of physicians specializing in cancer genomics, subsequently conducting a verification trial for the technology.

This is accomplished by integrating Fujitsu’s AI technology for language processing, which identifies terms and phrases used in research papers from context, as well as insight of information needed to discuss treatment policies identified by the Institute of Medical Science at the University of Tokyo.

Verification Trial Details With the newly developed technology, 2. 4 million elements of relationships from 860,000 medical papers are automatically extracted as knowledge to construct a knowledge graph database for cancer genomic medicine.

In this study, the time required for 4 physicians specializing in hematological malignancies at the Institute of Medical Science at the University of Tokyo to search and examine papers using the technology based on past cases of acute myeloid leukemia is measured, and the efficiency of examination work with and without the newly developed technology is evaluated.

Concepts Keywords
Acute Myeloid Leukemia Economy of Japan
Drug Side Effects Medical genetics
Fujitsu Industries
Fujitsu Laboratories Ltd Biotechnology
Fujitsu Limited Genomics
Genomic Medicine Treatment patient Technology
Genomics Verification trial technology
Germany Furukawa Group
Graph Companies
Graph Database Fujitsu
Hematological Malignancies Cancer research
Hematology Likelihood disease
Insurance Acute myeloid leukemia
Japan Insurance industry experts
Leukemia Technology elements relationships
Munich Verification trial technology
Mutation Leukemia
Oncology
Seiya
Tokyo

Semantics

Type Source Name
disease MESH cancer
disease DOID cancer
gene UNIPROT ANP32B
gene UNIPROT TNFSF13
disease DOID acute myeloid leukemia
pathway BSID Acute myeloid leukemia
disease MESH hematological malignancies
gene UNIPROT EHD1
disease MESH Development
gene UNIPROT KCNK3
disease MESH leukemia
disease DOID leukemia

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *